NCT07491497 2026-04-14
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
TRIANA Biomedicines, Inc.
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT05482087 2022-08-01
A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 2 Unknown
NCT04009317 2019-10-30
Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Unknown
NCT04056572 2019-10-30
Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Unknown